Stocktoria
Raia Drogasil S.A. RADL3.SA
BR · B3 (Brasil Bolsa) · XBSP · stock · Healthcare · website
Raia Drogasil S.A. financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $44.3B | $38.9B | $34.0B | $29.1B |
| Gross profit | $13.0B | $11.6B | $10.2B | $8.8B |
| SG&A expense | $10.3B | $9.2B | $8.2B | $7.1B |
| Operating income | $2.6B | $2.4B | $2.0B | $1.9B |
| Interest expense | $1.1B | $812.7M | $737.8M | $559.2M |
| Income tax | $147.8M | $207.6M | $129.6M | $178.2M |
| Net income | $1.3B | $1.2B | $1.1B | $996.1M |
| EPS (diluted) | $0.78 | $0.71 | $0.63 | $0.59 |
| Operating cash flow | $1.5B | $1.9B | $962.5M | $839.3M |
| Free cash flow | $106.5M | $628.9M | -$342.0M | -$349.4M |
| Cash & equivalents | $509.6M | $528.0M | $412.3M | $433.5M |
| Inventory | $9.6B | $8.4B | $7.2B | $6.1B |
| Total assets | $25.2B | $22.2B | $20.1B | $17.2B |
| Total liabilities | $17.8B | $15.7B | $14.1B | $11.8B |
| Shareholders' equity | $7.3B | $6.4B | $6.0B | $5.3B |
Growth · year-over-year · Revenue CAGR 15%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +13.8% | +14.4% | +16.9% | — |
| Net income growth | +8.1% | +13.7% | +5.9% | — |
| EPS growth | +10.0% | +12.0% | +7.4% | — |
| Free cash flow growth | -83.1% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · BR · as of 2025-12-31. Figures in BRL; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.